Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Arm, Single Sequence, Multiple Ascending Dose Study of the Safety and Tolerability of AB-2004 in a Pediatric Autism Spectrum Disorder Population

Next Previous
Trial Profile

A Single-Arm, Single Sequence, Multiple Ascending Dose Study of the Safety and Tolerability of AB-2004 in a Pediatric Autism Spectrum Disorder Population

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AB 2004 (Primary)
  • Indications Autism spectrum disorder
  • Focus Adverse reactions
  • Sponsors Axial Therapeutics

Most Recent Events

  • 14 Feb 2022 According to an Axial Biotherapeutics media release, status changed from active, no longer recruiting to completed.
  • 14 Feb 2022 According to an Axial Biotherapeutics media release, Robert L. Hendren, D.O., professor, psychiatry, Weill Institute for Neurosciences at the University of California, San Francisco, School of Medicine, is the principal investigator for the AB-2004 Phase 2 trial
  • 14 Feb 2022 According to an Axial Biotherapeutics media release, Nature Medicine Publishes Full Results from Axial Therapeutics Phase 1b/2a Clinical Trial in Autism Spectrum Disorder (ASD)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top